



assisTek announces First Clinical Trial to Collect Electronic Diary Data on Android Touch Screen Tablets in Patients' Homes

assisTek, the Leader in Innovative Electronic Patient Reported Outcomes (ePRO) Solutions and Patient Questionnaires for Clinical Trials announces that has been awarded an important clinical trial to collect Electronic Diary data from patients at home on new state-of-the-art Android tablet computers.

May 20, 2011, Scottsdale, AZ. assisTek, the [Leader in Innovative Electronic Patient Reported Outcomes \(ePRO\) Solutions and Patient Questionnaires for Clinical Trials](#) announces today that it will be providing state-of-the-art **Android Tablet computers** to collect electronic diary data from patients at home in an important upcoming clinical trial. assisTek's new offering, the Trial Tablet once again leads the eDiary and clinical trials market with solutions that bring SIGNIFICANT advantages to study sponsors and patients enrolled in clinical trials. Trial Tablet combines the advantages of the large screen, the portability of a PDA, and the data communications of a cell phone.



The Trial Tablet Solution offers many benefits to clinical trial sponsors. First, the Trial Tablet solution offers the sponsor unequalled access to data. With assisTek's new Trial Tablet offering, all data gets transferred automatically through the local cell phone network. Clinical trial teams have vastly improved access to data compared to PDAs or Palm devices because there is no longer a delay between when patients enter data and when they actually transfer data (and they have remembered and have overcome their data transfer problems). 99%+ of data entered by patients is available to the study team at all times. This real time data access to 99%+ of the study data enables the study team to truly monitor compliance, assess study status, and manage the study real time.

“ We are very proud to once again lead the ePRO market by offering ePRO solutions on the new touch screen tablets ”

most easily seen on a larger screen, which enables the patient to easily and reliably enter data with accuracy and precision.

Second, the tablet offers study sponsors outstanding data quality. Large screens with large font and buttons that are clearer and easier to use and result in more accurate patient answers and higher quality data. Further, large screens enable all the relevant data on a single PRO concept to be captured accurately on a single screen. For example, the detail on a body pain diagram, a sleep scale, or a stool scale can be

Third, it is not necessary to re-validate original paper questionnaires with the tablets. Questionnaires can be fully supported without modification on a large screen: no need to shorten the text or break a question into several screens to fit on a small-screen device. Therefore there is no need to commission a validation study to ensure the psychometric properties of the original questionnaire have not been changed.

Fourth, the tablet makes patients and site coordinators happy. Tablets have screens that are 4–5 times larger than Palms or PDAs. This significantly improves readability of questions and answer text and provides patients with a much more friendly and positive experience. In addition, assisTek's Trial Tablet is easier to use than a PDA because the patient does not need to set up telecommunications cradles or a landline connection. This means fewer things that can go wrong, resulting in fewer support calls. Fewer problems and support calls makes everybody positive about the trial which increases the chance of success day-to-day as well as at the conclusion of the trial.

The tablets also offer overall lower cost. First, the price of the devices is in the same range as other devices commonly used for eDiary applications, and assisTek's buy-back option makes the devices highly affordable. Second, there is no need for a costly validation or equivalence study as mentioned above. Third, because data is transferred automatically, support costs are negligible.

"We are very proud to once again lead the ePRO market by offering ePRO solutions on the new Android tablets," said Joy Hebert, Chief Operating Officer of assisTek. "As market leaders, we introduced the collection of patient reported outcomes on smart phones and netbooks in the last two years, and are proud to now deliver this new breakthrough product this year. Not only does this technology significantly reduce the work and hassle factor in collecting data from patients, it is also a beautiful product. It includes striking colors and photos will engage patients and encourage compliance much more effectively than older technologies offered by other vendors. "

About assisTek

assisTek is the global leader in ePRO systems and has revolutionized the process of collecting patient-reported outcomes in clinical trials by helping sites collect the data electronically through innovation, using touch-screens tablets, internet, Apple iPhones/smart phones, and tablets. For more information about assisTek's ePRO systems or to schedule a free no-obligation demonstration, contact assisTek.

The assisTek team has more than 45,000 patients in more than 35 therapeutic areas at more than 4,500 sites across 5 continents. Visit assisTek online www.assisTek.com

For more information:

Theron Taber

Executive VP

assisTek

480-874-9400 x 333

theron.taber@assisTek.com